Strengthening the Interface of Evidence-Based Decision Making Across European Regulators and Health Technology Assessment Bodies

Ella Jansen, Philip A. Hines, Michael Berntgen, Angela Brand

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Objectives: Access to medicines in Europe depends on a benefit-risk decision taken by regulators and a relative effectiveness assessment performed by health technology assessment bodies (HTABs) to inform, as one element, a reimbursement decision. Although various similarities in evidence needs exist, understanding of their needs is currently suboptimal and therefore the evidence generated does not always meet their needs. Subsequently, delays in decision making can be expected, negatively affecting access. To overcome this, this study reviewed the evidentiary needs of European regulators and HTABs at European level and analyzed how their collaboration can further facilitate optimal evidence generation plans, evidence use, and evidence presentation. Methods: Through systematic literature review, expert interviews, and pairwise comparison of assessment reports by the European Medicines Agency and European network for health technology assessment, respective clinical evidence requirements and impact of product-specific collaboration between European Medicines Agency and HTABs were established. Results: Clinical evidence needs are quite similar but differences exist in comparator choice, preferred efficacy endpoints, and target population. Results of the impact of collaboration to date were mixed: preapproval joint advice procedures were successful and highly valued by all stakeholders; information exchange at the time of regulatory decision is coming together, yet the European Public Assessment Report can be further optimized; and collaboration on postlicensing evidence generation requirements shows potential but needs solidifying. Conclusions: These findings demonstrate the potential to further improve the evidence utilization across stakeholders to avoid duplication and streamline decision making, to ultimately improve access to medicines for European patients.

Original languageEnglish
Pages (from-to)1726-1735
Number of pages10
JournalValue in Health
Issue number10
Publication statusPublished - 10-2022

All Science Journal Classification (ASJC) codes

  • Health Policy
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Strengthening the Interface of Evidence-Based Decision Making Across European Regulators and Health Technology Assessment Bodies'. Together they form a unique fingerprint.

Cite this